Press release
May 7, 2026
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
GENELUX Corp (GNLX)
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and